EP1023076A4 - Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer - Google Patents

Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer

Info

Publication number
EP1023076A4
EP1023076A4 EP98908523A EP98908523A EP1023076A4 EP 1023076 A4 EP1023076 A4 EP 1023076A4 EP 98908523 A EP98908523 A EP 98908523A EP 98908523 A EP98908523 A EP 98908523A EP 1023076 A4 EP1023076 A4 EP 1023076A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
cancer
treatment
tumor suppressor
suppressor gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98908523A
Other languages
German (de)
English (en)
Other versions
EP1023076A1 (fr
Inventor
Ramon E Parsons
Michael H Wigler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Columbia University in the City of New York
Original Assignee
Cold Spring Harbor Laboratory
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory, Columbia University in the City of New York filed Critical Cold Spring Harbor Laboratory
Publication of EP1023076A1 publication Critical patent/EP1023076A1/fr
Publication of EP1023076A4 publication Critical patent/EP1023076A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98908523A 1997-02-07 1998-02-06 Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer Withdrawn EP1023076A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3694397P 1997-02-07 1997-02-07
US36943P 1997-02-07
PCT/US1998/002615 WO1998034624A1 (fr) 1997-02-07 1998-02-06 Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer

Publications (2)

Publication Number Publication Date
EP1023076A1 EP1023076A1 (fr) 2000-08-02
EP1023076A4 true EP1023076A4 (fr) 2001-11-21

Family

ID=21891553

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98908523A Withdrawn EP1023076A4 (fr) 1997-02-07 1998-02-06 Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer

Country Status (4)

Country Link
EP (1) EP1023076A4 (fr)
AU (1) AU6653698A (fr)
CA (1) CA2280097A1 (fr)
WO (1) WO1998034624A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
WO2004074459A2 (fr) * 2003-02-19 2004-09-02 Georgetown University Cellules deficientes en pten et utilisations de celles-ci
CN109022461B (zh) 2017-06-08 2022-01-14 中山大学附属第一医院 一种PTEN基因的上游开放阅读框45aa-uORF核苷酸序列及其编码的多肽的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033907A1 (fr) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System Suppresseur tumoral ts10q23.3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033907A1 (fr) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System Suppresseur tumoral ts10q23.3

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LI D-M ET AL: "TEP1, ENCODED BY A CANDIDATE TUMOR SUPPRESSOR LOCUS, IS A NOVEL PROTEIN TYROSINE PHOSPHATASE REGULATED BY TRANSFORMING GROWTH FACTOR BETA1-", CANCER RESEARCH, vol. 57, 1 June 1997 (1997-06-01), pages 2124 - 2129, XP002066157, ISSN: 0008-5472 *
LIAW DANNY ET AL: "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.", NATURE GENETICS, vol. 16, no. 1, 16 May 1997 (1997-05-16), pages 64 - 67, XP001024445, ISSN: 1061-4036 *
LO SU HAO ET AL: "Molecular cloning of chick cardiac muscle tensin: Full-length cDNA sequence, expression, and characterization.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 35, 1994, pages 22310 - 22319, XP002178161, ISSN: 0021-9258 *
MYERS ET AL: "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatse", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, 1 August 1997 (1997-08-01), pages 9052 - 9057, XP002088258, ISSN: 0027-8424 *
NELEN M R ET AL: "Localization of the gene for Cowden disease to chromosome 10q22-23.", NATURE GENETICS, vol. 13, no. 1, 1996, pages 114 - 116, XP001024519, ISSN: 1061-4036 *
See also references of WO9834624A1 *

Also Published As

Publication number Publication date
CA2280097A1 (fr) 1998-08-13
EP1023076A1 (fr) 2000-08-02
WO1998034624A1 (fr) 1998-08-13
AU6653698A (en) 1998-08-26

Similar Documents

Publication Publication Date Title
EP0831904A4 (fr) Traitement et diagnostic du cancer de la prostate
DE69529307D1 (de) Ultraschall-Diagnose- und Behandlungssystem
EP0696919A4 (fr) Diagnostic et traitement des dysfonctionnements erectiles
BR9707125A (pt) Composições e processos para o tratamento e diagnóstico de câncer de mama
EP0926955A4 (fr) Conjugues utiles dans le traitement du cancer de la prostate
DE69535509D1 (de) Medizinische diagnostische Bilddarstellungssystem und Verfahren
FI965095A7 (fi) Diatritsoksiesteri röntgenkontrastiaineina verenkiertojärjestelmän ja lymfaattisen järjestelmän kuvauksessa
DK0806968T3 (da) Diagnostiske billeddannelseskontrastmidler med foröget blodretention
EP0696175A4 (fr) Detection et diagnostic de traumas dans tissues corporelles
FR2777466B1 (fr) Appareil de traitement de tumeur
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
ZA982968B (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP0662001A4 (fr) Ligands multifonctionnels potentiellement utiles pour realiser des agents therapeutiques ou de diagnostic par imagerie radiopharmaceutique.
EP1567556A4 (fr) Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
EP1100524A4 (fr) Utilisation d'uteroglobine humaine de recombinaison dans le traitement d'etats inflammatoires et de type fibreux
EP1214040A4 (fr) Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer
EP1023076A4 (fr) Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer
AU1214995A (en) Cdna probe for breast cancer diagnosis and treatment
EP1546714A4 (fr) Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain
EP0907720A4 (fr) Radiotherapie et immunotherapie combinees pour le traitement du cancer
EP1409734A4 (fr) Diagnostic et traitement du cancer
EP1322778A4 (fr) Utilisation de cyr61 dans le traitement et le diagnostic des leiomyomes uterins chez la femme
EP0871472A4 (fr) Cytokines et leur utilisation dans le traitement et/ou la prophylaxie du cancer du sein
GB9908059D0 (en) Diagnosis and treatment of diseases
EP1157694A4 (fr) Agent therapeutique pour le traitement de la dyserection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011009

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030821